Citadel Advisors
PHAR

Citadel Advisors’s Pharming Group PHAR Stock Holding History

Citadel Advisors’s Portfolio PHAR Stock Details PHAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170K Sell
10,189
-7,501
-42% -$127K ﹤0.01% 11577
2025
Q4 		$313K Buy
+17,690
New +$278K ﹤0.01% 10043

Other funds holding PHAR

SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SHIM
Stone House Investment Management Tunkhannock, Pennsylvania $558M AUM 14.72% 1-Year Est. Return

Citadel Advisors's PHAR Position: Q1 2026 in Review

Citadel Advisors reduced its Pharming Group (PHAR) stake by 42% in Q1 2026, selling an estimated $127K and leaving 10,189 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #11577.

Citadel Advisors first reported a position in PHAR in Q4 2025 and has held it in 2 quarters since. The position peaked at $313K in Q4 2025. 12 funds tracked by Wall St. Rank hold PHAR as of Q1 2026.

  • Citadel Advisors held 10,189 shares of Pharming Group worth $170K as of Q1 2026.
  • Citadel Advisors sold 7,501 Pharming Group shares in Q1 2026, an estimated $127K.
  • Pharming Group made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11577 holding.
  • Citadel Advisors first reported a position in Pharming Group in Q4 2025 and has held it in 2 quarters since.
  • Citadel Advisors's Pharming Group position peaked at $313K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Pharming Group as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.